RETRACTED: Isovitexin modulates autophagy in Alzheimer's disease via miR-107 signalling (Retracted article. See vol. 13, pg. 407, 2022)

Background: - Alzheimer's disease (AD) is an ultimately fatal, degenerative brain disease in the elderly people. In the current work, we assessed the defensive capability of isovitexin (IVX) through an intracerebroventricular injection of streptozotocin (STZ)-induced AD mouse model. Methods: - Mice were separated into four cohorts: sham-operated control mice; STZ-intoxicated Alzheimer's mice; IVX cohort, IVX + STZ; and Ant-107 cohort, antagomiR-107 + IVX/STZ as in the IVX cohort. Results: - The outcomes indicated that IVX administration ameliorated spatial memory loss and blunted a cascade of neuro-noxious episodes - including increased amyloid-beta (A beta) and degraded myelin basic protein burden, neuroinflammation (represented by elevated caspase-1, TNF-alpha and IL-6 levels) and autophagic dysfunction (represented by altered LC3-II, Atg7 and beclin-1 expressions) - via the inhibition of PI3K/Akt/mTOR signalling axis. We considered the question of whether the epigenetic role of microRNA-107 (miR-107) has any impact on these events, by using antagomiR-107. Conclusion: - This probing underscored that miR-107 could be a pivotal regulatory button in the activation of molecular signals linked with the beneficial autophagic process and anti-inflammatory activities in relation to IVX treatment. Hence, this report exemplifies that IVX could guard against A beta toxicity and serve as an effectual treatment for patients afflicted with AD.